A high quality and consistent product, supported by consistent service and reliable supply, balanced against the very best price – and all with maximum sustainability benefit.
We know exactly what our pharma customers want from a CMO partner: Peace of mind. At DSM we provide it through the development and manufacturing of APIs and intermediates across the entire lifecycle. We cater to both large pharmas looking for specific expertise and additional capacity at maximum efficiency; and to smaller, emerging customers where our economies of scale, track record and regulatory support can accelerate and simplify production.
We offer you a range of early-stage R&D services as well as the development and production of materials for tox studies and clinical trials. Our ResCom® solution focuses on fast supply of clinical trials materials (cGMP as well as non-GMP) and includes the development and implementation of chemical processes based on drug discovery. We complement this with a range of analytical and investigational services all aimed at getting APIs through the pipeline as quickly and safely as possible.
The image shows the chemical structure of Aureobasidin A, a cyclic peptide antifungal compound.
Mechanism of Action
AbA targets inositol phosphorylceramide (IPC) synthase, an essential enzyme involved in the biosynthesis of sphingolipids in fungal cell membranes. Sphingolipids are crucial components of fungal cell membranes, and by inhibiting IPC synthase, AbA disrupts the formation of these essential membrane components, leading to cell death. This unique mode of action distinguishes AbA from other antifungal drugs that target different cellular pathways.
Antifungal Activity
AbA exhibits potent antifungal activity against a broad spectrum of fungal pathogens, including Candida species, Aspergillus species, and Cryptococcus neoformans. However, its use is limited by its relatively low solubility and bioavailability.
Addressing the Challenges
Researchers are actively exploring ways to overcome the limitations of AbA, such as its low solubility and limited activity against certain fungal species. Strategies include:
- Chemical modifications: Modifying the chemical structure of AbA to improve its solubility, bioavailability, and antifungal activity.
- Formulation development: Developing novel formulations to enhance the delivery and efficacy of AbA.
- Combination therapies: Combining AbA with other antifungal agents to achieve synergistic effects and broaden the spectrum of activity.
Future Outlook
Despite the challenges, AbA remains a promising candidate for the development of novel antifungal drugs. Continued research efforts focused on optimizing its properties and exploring new delivery strategies may lead to the development of effective treatments for a range of fungal infections.
Keywords: Aureobasidin A, antifungal, drug discovery, drug resistance, fungal infections, Candida, Aspergillus, Cryptococcus, sphingolipids, IPC synthase, chemical modifications, drug delivery, combination therapy